Improved Treatment Results in Childhood Acute Nonlymphoblastic Leukemia with the BFM-AML Protocol 78 in a Multicenter Study in the GDR

Publisher Website
Google Scholar
Abstract
In contrast to recent advances in the treatment of acute lymphoblastic leukemia (ALL) where cure rates of nearly 70% have been obtained [1, 2], the outcome of the treatment for acute nonlymphoblastic leukemia (ANLL, AML) is less successful. In general, remission rates of about 70% have been obtained [3–9]. But the relapse rate is high, and so CCR rates of 50% after 2–3 years are exceptions [3, 4, 10].